Rhodium(III)-catalyzed [4 + 2] annulation of N-arylbenzamidines with 1,4,2-dioxazol-5-ones: Easy access to 4-aminoquinazolines via highly selective C H bond activation
Synthesis, 2D-QSAR Studies and Biological Evaluation of Quinazoline Derivatives as Potent Anti-Trypanosoma cruzi Agents
作者:Mariela Bollini、Ana M. Bruno、María E. Niño、Juan J. Casal、Leandro D. Sasiambarrena、Damián A.G. Valdez、Leandro Battini、Vanesa R. Puente、María E. Lombardo
DOI:10.2174/1573406414666181005145042
日期:2019.4.12
disease. Therefore, continuous research is an urgent need so as to discover novel therapeutic alternatives. Objective: The development of safer and more efficient therapeutic anti-T. cruzi drugs continues to be a major goal in trypanocidal chemotherapy. Method: Synthesis, 2D-QSAR and drug-like physicochemical properties of a set of quinazolinone and quinazolinederivatives were studied as trypanocidal
gave respective 2-amino-N-arylbenzamidines. 4-Arylaminoquinazolines lacking a substituent at the 2 position were obtained directly by heating 2-amino-N-arylbenzamidines in formic acid; in similar conditions other carboxylic acids did not react with the amidines. The latter when treated with aldehydes afforded 2-aryl-4-arylimino-1H-2,3-dihydroquinazolines readily oxidizable by potassium permanganate to
在氯化铝存在下用苯胺处理的2-氨基苄腈分别得到2-氨基-N-芳基苯甲m。通过在甲酸中加热2-氨基-N-芳基苯甲m直接获得在2位上没有取代基的4-芳基氨基喹唑啉;在类似条件下,其他羧酸不与the反应。当用醛处理时,后者得到2-芳基-4-芳基氨基-1 H -2,3-二氢喹唑啉易于被高锰酸钾氧化成2-芳基-4-芳基氨基喹唑啉。
THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE
申请人:Suzuki Masaki
公开号:US20150307477A1
公开(公告)日:2015-10-29
Methods of treating disorders using compounds that modulate striatal-enriched tyrosine phosphatase (STEP) are described herein. Exemplary disorders include schizophrenia and cognitive deficit.
Synthesis of quinazolinones from anthranilamides and aldehydes via metal-free aerobic oxidation in DMSO
作者:Na Yeun Kim、Cheol-Hong Cheon
DOI:10.1016/j.tetlet.2014.02.065
日期:2014.4
A highly environmentally benign protocol for the synthesis of quinazolinones from anthranilamides and aldehydes via aerobicoxidation was developed in wet DMSO. This protocol is operationally simple, exhibits broad substrate scope, and does not need toxic metal catalysts and bases. In addition, the utility of this transformation was further demonstrated by converting the resulting quinazolinones into
申请人:Korea University Research and Business Foundation 고려대학교 산학협력단(220040170680) BRN ▼209-82-08298
公开号:KR101580821B1
公开(公告)日:2015-12-30
본 발명은 금속과 염기가 배제된 디메틸설폭사이드(dimethylsulfoxid, DMSO) 용매하에서 산소원를 산화제로 사용하는 호기성 산화법을 이용하여 퀴나졸리논 유도체를 제조하는 방법에 관한 것으로, 본 발명에 따른 퀴나졸리논 유도체의 제조방법은 팔라듐이나 이리듐 등과 같은 금속촉매를 필요로 하지 않아 잔존하는 금속에 의한 독성문제가 없으며, 강한 산 또는 염기조건, 저온 반응 및 무수조건의 반응과 같은 까다로운 공정을 필요로 하지 않으며, 별도의 정제공정을 필요로 하지 않아 경제적이고, 간단하게 안트라닐아미드 유도체와 알데히드원을 반응시켜 퀴나졸리논 유도체를 도입할 수 있다.